Teneligliptin Hydrobromide (CAS 906093-29-6, MP-513) is a long-acting oral selective DPP-4 inhibitor API approved in Japan for Type 2 Diabetes Mellitus treatment. Featured excellent water solubility and stable pharmacokinetics, no dose adjustment required for hepatic/renal impaired patients. Our pharma-grade raw powder ≥99% HPLC purity supports bulk kg shipment & lab small sample supply for formulation & preclinical research.
| Item |
Details |
| Product Name |
Teneligliptin Hydrobromide |
| CAS No. |
906093-29-6 |
| Synonyms |
MP-513 Hydrobromide; Tenelia; |
| Chemical Name |
(3S,5R)-1-[1-Phenyl-3-methylpyrazol-5-yl]-5-(1,3-thiazolidine-3-carbonyl)piperidin-3-amine 2.5Hydrobromide |
| Molecular Formula |
C22H30N6OS⋅2.5HBr |
| Molecular Weight |
628.86 |
| Free Base MW |
426.58 |
| Appearance |
White to off-white crystalline powder |
| Purity |
≥99.0% HPLC (JP/EP Pharma Grade) |
| Specific Rotation |
[α]D25:-28° ~ -36° (c=0.5, Methanol) |
| Solubility |
Water ≥200 mg/mL; DMSO≥100 mg/mL; Sparingly soluble in Ethanol(≈17mg/mL) |
| Storage |
Sealed, 2~8℃ dry & away from light; Long-term: -20℃ sealed desiccation |
| Target Enzyme |
DPP-4(Dipeptidyl Peptidase 4), IC₅₀≈1nM(human DPP4) |
| Mechanism |
Selective competitive DPP-4 inhibitor, prolong endogenous GLP‑1 half-life, boost insulin secretion & suppress glucagon release to lower fasting/postprandial blood glucose |
| Application |
1. API for oral anti-type 2 diabetes tablets(Original brand Tenelia®, Mitsubishi Tanabe Pharma Japan)
2. Clinical daily dosage: 20~40mg Q.D oral
3. Lab research DPP4 inhibitor reagent for diabetes pharmacology test |
| Pharmacopoeia Standard |
JP 18, In-house Pharma Specification |
